Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.

Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y

by Zacks Equity Research

Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.

QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View

by Zacks Equity Research

QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.

PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Ecolab (ECL) gains from solid segmental contributions in the second quarter. It retains 2019 EPS view.

Baxter (BAX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View

by Zacks Equity Research

Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.

Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 9.88% and 1.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Roster for Jul 25: SYK, BAX & More

by Urmimala Biswas

Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.

Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.

Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

Tirthankar Chakraborty headshot

Trump's Order on Kidney Care Lifts These Dialysis Stocks

by Tirthankar Chakraborty

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Patterson Companies' (PDCO) Earnings Miss Estimates in Q4

by Zacks Equity Research

Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.

Mark Vickery headshot

Top Analyst Reports for ExxonMobil, Oracle & ADP

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Oracle (ORCL) and ADP (ADP).

Here's Why You Should Hold Baxter International (BAX) for Now

by Zacks Equity Research

Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.

Baxter (BAX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

QDEL vs. BAX: Which Stock Is the Better Value Option?

by Zacks Equity Research

QDEL vs. BAX: Which Stock Is the Better Value Option?

Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment

by Zacks Equity Research

Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.

Baxter (BAX) Down 1.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Research Reports for Cigna, EOG Resources & Northrop Grumman

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Cigna (CI), EOG Resources (EOG) and Northrop Grumman (NOC).

BAX vs. CLPBY: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAX vs. CLPBY: Which Stock Is the Better Value Option?

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.

Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter International Inc. (BAX) reports solid Q1 performance on the back of higher revenues and strong operating margin.